Dimethyl fumarate DR is a Small Molecule owned by Almirall, and is involved in 9 clinical trials, which were completed.

Dimethyl fumarate acts as an antipsoriatic agent with immunomodulating properties. The immune system is a network of special cells, proteins, tissues and organs that prevents the infection and growth of bacteria, viruses and parasites in the body. It also prevents the uncontrolled growth of rogue cells or cancerous cells. In most cases, the immune system does a great job of keeping people healthy and preventing infections.

The revenue for Dimethyl fumarate DR is expected to reach a total of $748m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Dimethyl fumarate DR NPV Report.

Dimethyl fumarate DR is currently owned by Almirall.

Dimethyl fumarate DR Overview

Dimethyl fumarate (LAS-41008, Skilarence) is the methyl ester of fumaric acid, acts as an anti-inflammatory and immunomodulatory agent. It is formulated as gastro-resistant film coated tablets and tablets for oral route of administration. Skilarence is indicated for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.

Almirall Overview

Almirall is a specialty pharmaceutical company that researches, develops, manufactures, and commercializes proprietary medicines and licensed products. The company’s major area of focus is dermatology covering psoriasis, eczema, acne, and other skin infections. It also develops products for autoimmune diseases including rheumatoid arthritis and multiple sclerosis; and gastrointestinal diseases including irritable bowel syndrome with constipation. The company also works together with small and medium-sized companies and healthcare professionals to develop medical solutions and provide them to patients. It operates through affiliates in Europe and Central America and has R&D centers in Spain and Germany. Almirall is headquartered in Barcelona, Spain.

The company reported revenues of (Euro) EUR827.2 million for the fiscal year ended December 2021 (FY2021), an increase of 2.4% over FY2020. In FY2021, the company’s operating margin was 0.7%, compared to an operating margin of 11.4% in FY2020. The net loss of the company was EUR40.9 million in FY2021, compared to a net profit of EUR74.3 million in FY2020. The company reported revenues of EUR197.2 million for the third quarter ended September 2022, a decrease of 54.8% over the previous quarter.

Quick View – Dimethyl fumarate DR

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Dimethyl fumarate DR
Administration Pathway
  • Oral
Therapeutic Areas
  • Immunology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.